Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
04 May 2019
Historique:
received: 05 05 2018
revised: 19 12 2018
accepted: 15 01 2019
pubmed: 10 4 2019
medline: 23 5 2019
entrez: 10 4 2019
Statut: ppublish

Résumé

Routine childhood vaccination is among the most cost-effective, successful public health interventions available. Amid substantial investments to expand vaccine delivery throughout Africa and strengthen administrative reporting systems, most countries still require robust measures of local routine vaccine coverage and changes in geographical inequalities over time. This analysis drew from 183 surveys done between 2000 and 2016, including data from 881 268 children in 49 African countries. We used a Bayesian geostatistical model calibrated to results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017, to produce annual estimates with high-spatial resolution (5 ×    5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for children aged 12-23 months in 52 African countries from 2000 to 2016. Estimated third-dose (DPT3) coverage increased in 72·3% (95% uncertainty interval [UI] 64·6-80·3) of second-level administrative units in Africa from 2000 to 2016, but substantial geographical inequalities in DPT coverage remained across and within African countries. In 2016, DPT3 coverage at the second administrative (ie, district) level varied by more than 25% in 29 of 52 countries, with only two (Morocco and Rwanda) of 52 countries meeting the Global Vaccine Action Plan target of 80% DPT3 coverage or higher in all second-level administrative units with high confidence (posterior probability ≥95%). Large areas of low DPT3 coverage (≤50%) were identified in the Sahel, Somalia, eastern Ethiopia, and in Angola. Low first-dose (DPT1) coverage (≤50%) and high relative dropout (≥30%) together drove low DPT3 coverage across the Sahel, Somalia, eastern Ethiopia, Guinea, and Angola. Despite substantial progress in Africa, marked national and subnational inequalities in DPT coverage persist throughout the continent. These results can help identify areas of low coverage and vaccine delivery system vulnerabilities and can ultimately support more precise targeting of resources to improve vaccine coverage and health outcomes for African children. Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND BACKGROUND
Routine childhood vaccination is among the most cost-effective, successful public health interventions available. Amid substantial investments to expand vaccine delivery throughout Africa and strengthen administrative reporting systems, most countries still require robust measures of local routine vaccine coverage and changes in geographical inequalities over time.
METHODS METHODS
This analysis drew from 183 surveys done between 2000 and 2016, including data from 881 268 children in 49 African countries. We used a Bayesian geostatistical model calibrated to results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017, to produce annual estimates with high-spatial resolution (5 ×    5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for children aged 12-23 months in 52 African countries from 2000 to 2016.
FINDINGS RESULTS
Estimated third-dose (DPT3) coverage increased in 72·3% (95% uncertainty interval [UI] 64·6-80·3) of second-level administrative units in Africa from 2000 to 2016, but substantial geographical inequalities in DPT coverage remained across and within African countries. In 2016, DPT3 coverage at the second administrative (ie, district) level varied by more than 25% in 29 of 52 countries, with only two (Morocco and Rwanda) of 52 countries meeting the Global Vaccine Action Plan target of 80% DPT3 coverage or higher in all second-level administrative units with high confidence (posterior probability ≥95%). Large areas of low DPT3 coverage (≤50%) were identified in the Sahel, Somalia, eastern Ethiopia, and in Angola. Low first-dose (DPT1) coverage (≤50%) and high relative dropout (≥30%) together drove low DPT3 coverage across the Sahel, Somalia, eastern Ethiopia, Guinea, and Angola.
INTERPRETATION CONCLUSIONS
Despite substantial progress in Africa, marked national and subnational inequalities in DPT coverage persist throughout the continent. These results can help identify areas of low coverage and vaccine delivery system vulnerabilities and can ultimately support more precise targeting of resources to improve vaccine coverage and health outcomes for African children.
FUNDING BACKGROUND
Bill & Melinda Gates Foundation.

Identifiants

pubmed: 30961907
pii: S0140-6736(19)30226-0
doi: 10.1016/S0140-6736(19)30226-0
pmc: PMC6497987
pii:
doi:

Substances chimiques

Diphtheria-Tetanus-Pertussis Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1843-1855

Subventions

Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : T32 HD007242
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Bull World Health Organ. 2008 Mar;86(3):A-B
pubmed: 18368190
Bull World Health Organ. 2009 Jul;87(7):535-41
pubmed: 19649368
Vaccine. 2011 Oct 26;29(46):8215-21
pubmed: 21893149
Vaccine. 2012 Dec 17;31(1):96-108
pubmed: 23142307
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Health Aff (Millwood). 2016 Feb;35(2):242-9
pubmed: 26858376
Health Aff (Millwood). 2016 Feb;35(2):250-8
pubmed: 26858377
Lancet Glob Health. 2016 Oct;4(10):e726-35
pubmed: 27569362
N Engl J Med. 2016 Dec 22;375(25):2435-2445
pubmed: 27723434
Sci Data. 2017 Jan 31;4:170004
pubmed: 28140397
Bull World Health Organ. 2017 Sep 1;95(9):629-638
pubmed: 28867843
Lancet. 2017 Sep 16;390(10100):1423-1459
pubmed: 28916366
Lancet. 2017 Sep 16;390(10100):1084-1150
pubmed: 28919115
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
J R Soc Interface. 2017 Sep;14(134):
pubmed: 28931634
Lancet. 2017 Nov 11;390(10108):2171-2182
pubmed: 28958464
Nature. 2017 Nov 16;551(7680):273
pubmed: 29144479
Vaccine. 2018 Mar 14;36(12):1583-1591
pubmed: 29454519
Nature. 2018 Feb 28;555(7694):48-53
pubmed: 29493588
Nature. 2018 Feb 28;555(7694):41-47
pubmed: 29493591

Auteurs

Jonathan F Mosser (JF)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

William Gagne-Maynard (W)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Puja C Rao (PC)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Aaron Osgood-Zimmerman (A)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Nancy Fullman (N)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Nicholas Graetz (N)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Roy Burstein (R)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Rachel L Updike (RL)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Patrick Y Liu (PY)

David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Sarah E Ray (SE)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Lucas Earl (L)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Aniruddha Deshpande (A)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Daniel C Casey (DC)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Laura Dwyer-Lindgren (L)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Elizabeth A Cromwell (EA)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA.

David M Pigott (DM)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA.

Freya M Shearer (FM)

Big Data Institute, University of Oxford, Oxford, UK.

Heidi Jane Larson (HJ)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Daniel J Weiss (DJ)

Big Data Institute, University of Oxford, Oxford, UK.

Samir Bhatt (S)

Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.

Peter W Gething (PW)

Big Data Institute, University of Oxford, Oxford, UK.

Christopher J L Murray (CJL)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA.

Stephen S Lim (SS)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA. Electronic address: stevelim@uw.edu.

Robert C Reiner (RC)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA.

Simon I Hay (SI)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA. Electronic address: sihay@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH